nach oben

Current Hematologic Malignancy Reports

Erschienen in:

01.09.2015 | B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Armitage, Section Editor)

To Each Its Own: Linking the Biology and Epidemiology of NHL Subtypes

verfasst von: Jean L. Koff, Dai Chihara, Anh Phan, Loretta J. Nastoupil, Jessica N. Williams, Christopher R. Flowers

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Non-Hodgkin lymphoma (NHL) constitutes a diverse group of more than 40 subtypes, each characterized by distinct biologic and clinical features. Until recently, pinpointing genetic and epidemiologic risk factors for individual subtypes has been limited by the relative rarity of each. However, several large pooled case-control studies have provided sufficient statistical power for detecting etiologic differences and commonalities between subtypes and thus yield new insight into their unique epidemiologic backgrounds. Here, we review the subtype-specific medical, lifestyle, and biologic components identified in these studies, which suggest that a complex interplay between host genetics, autoimmune disorders, modifiable risk factors, and occupation contributes to lymphomagenesis.

Ferlay J, SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. <http://globocan.iarc.fr> (2013).

Chihara D et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164:536–45. doi:10.1111/bjh.12659.PubMedCentralCrossRefPubMed

Sant M et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724–34. doi:10.1182/blood-2010-05-282632.CrossRefPubMed

Morton LM et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265–76. doi:10.1182/blood-2005-06-2508.PubMedCentralCrossRefPubMed

Kane EV et al. Postmenopausal hormone therapy and non-Hodgkin lymphoma: a pooled analysis of InterLymph case-control studies. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24:433–41. doi:10.1093/annonc/mds340.CrossRef

Hjalgrim H et al. Cigarette smoking and risk of Hodgkin lymphoma: a population-based case-control study. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2007;16:1561–6. doi:10.1158/1055-9965.epi-07-0094.CrossRef

Gibson TM et al. Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium. Cancer Causes Control CCC. 2013;24:125–34. doi:10.1007/s10552-012-0098-4.PubMedCentralCrossRefPubMed

Cocco P et al. Occupational exposure to trichloroethylene and risk of non-Hodgkin lymphoma and its major subtypes: a pooled InterLymph [correction of IinterLlymph] analysis. Occup Environ Med. 2013;70:795–802. doi:10.1136/oemed-2013-101551.CrossRefPubMed

Nieters A et al. PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma: results from the InterLymph consortium. Blood. 2012;120:4645–8. doi:10.1182/blood-2012-05-427989.PubMedCentralCrossRefPubMed

10.

Kane EV et al. Menstrual and reproductive factors, and hormonal contraception use: associations with non-Hodgkin lymphoma in a pooled analysis of InterLymph case-control studies. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2012;23:2362–74. doi:10.1093/annonc/mds171.CrossRef

11.

Turner JJ et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood. 2010;116:e90–8. doi:10.1182/blood-2010-06-289561.PubMedCentralCrossRefPubMed

12.

Skibola CF et al. Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph consortium. Am J Epidemiol. 2010;171:267–76. doi:10.1093/aje/kwp383.PubMedCentralCrossRefPubMed

13.

Vajdic CM et al. Atopic disease and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis. Cancer Res. 2009;69:6482–9. doi:10.1158/0008-5472.can-08-4372.PubMedCentralCrossRefPubMed

14.

Willett EV et al. Non-Hodgkin lymphoma and obesity: a pooled analysis from the InterLymph consortium. Int J Cancer. 2008;122:2062–70. doi:10.1002/ijc.23344.PubMedCentralCrossRefPubMed

15.

Kricker A et al. Personal sun exposure and risk of non Hodgkin lymphoma: a pooled analysis from the Interlymph consortium. Int J Cancer. 2008;122:144–54. doi:10.1002/ijc.23003.CrossRefPubMed

16.

Ekstrom Smedby K et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph consortium. Blood. 2008;111:4029–38. doi:10.1182/blood-2007-10-119974.PubMedCentralCrossRefPubMed

17.

Wang SS et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the international lymphoma epidemiology consortium (InterLymph). Blood. 2007;109:3479–88. doi:10.1182/blood-2006-06-031948.PubMedCentralCrossRefPubMed

18.

Morton LM et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the pathology working group of the international lymphoma epidemiology consortium (InterLymph). Blood. 2007;110:695–708. doi:10.1182/blood-2006-11-051672.PubMedCentralCrossRefPubMed

19.

Rothman N et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph consortium. Lancet Oncol. 2006;7:27–38. doi:10.1016/s1470-2045(05)70434-4.CrossRefPubMed

20.

Morton LM et al. Cigarette smoking and risk of non-Hodgkin lymphoma: a pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymph). Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2005;14:925–33. doi:10.1158/1055-9965.epi-04-0693.CrossRef

21.

Taccioli GE et al. Impairment of V(D)J recombination in double-strand break repair mutants. Science (New York, NY). 1993;260:207–10.CrossRef

22.

Li Z, Woo CJ, Iglesias-Ussel MD, Ronai D, Scharff MD. The generation of antibody diversity through somatic hypermutation and class switch recombination. Genes Dev. 2004;18:1–11. doi:10.1101/gad.1161904.CrossRefPubMed

23.

Costello R et al. Peripheral T-cell lymphoma gene expression profiling and potential therapeutic exploitations. Br J Haematol. 2010;150:21–7. doi:10.1111/j.1365-2141.2009.07977.x.PubMed

24.

Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. J Clin Invest. 2012;122:3424–31. doi:10.1172/jci63186.PubMedCentralCrossRefPubMed

25.

Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2011;117:26–38. doi:10.1182/blood-2010-04-189977.PubMedCentralCrossRefPubMed

26.

Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol. 2002;2:920–32. doi:10.1038/nri953.CrossRefPubMed

27.

Lenz G et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med. 2007;204:633–43. doi:10.1084/jem.20062041.PubMedCentralCrossRefPubMed

28.

Ferreri AJ, Govi S, Pileri SA, Savage KJ. Anaplastic large cell lymphoma, ALK-positive. Crit Rev Oncol Hematol. 2012;83:293–302. doi:10.1016/j.critrevonc.2012.02.005.CrossRefPubMed

29.

Xu-Monette ZY et al. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood. 2012;119:3668–83. doi:10.1182/blood-2011-11-366062.PubMedCentralCrossRefPubMed

30.

Shaffer 3rd AL, Young RM, Staudt LM. Pathogenesis of human B cell lymphomas. Annu Rev Immunol. 2012;30:565–610. doi:10.1146/annurev-immunol-020711-075027.CrossRefPubMed

31.••

Vajdic CM et al. Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014:87–97. doi:10.1093/jncimonographs/lgu002. The largest pooled analysis of epidemiological risk factors for patients with lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinemia.

32.••

Slager SL et al. Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014:41–51. doi:10.1093/jncimonographs/lgu001. The largest pooled analysis of epidemiological risk factors for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

33.••

Mbulaiteye SM et al. Medical history, lifestyle, family history, and occupational risk factors for sporadic Burkitt lymphoma/leukemia: the Interlymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014:106–14. doi:10.1093/jncimonographs/lgu003. The largest pooled analysis of epidemiological risk factors for patients with Burkitt lymphoma.

34.••

Linet MS et al. Medical history, lifestyle, family history, and occupational risk factors for follicular lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014:26–40. doi:10.1093/jncimonographs/lgu006. The largest pooled analysis of epidemiological risk factors for patients with follicular lymphoma.

35.••

Cerhan JR et al. Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014:15–25. doi:10.1093/jncimonographs/lgu010. The largest pooled analysis of epidemiological risk factors for patients with diffuse large B-cell lymphoma.

36.••

Smedby KE et al. Medical history, lifestyle, family history, and occupational risk factors for mantle cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014:76–86. doi:10.1093/jncimonographs/lgu007. The largest pooled analysis of epidemiological risk factors for patients with mantle cell lymphoma.

37.

Skibola CF et al. Medical history, lifestyle, family history, and occupational risk factors for adult acute lymphocytic leukemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014:125–9. doi:10.1093/jncimonographs/lgu009.PubMedCentralCrossRefPubMed

38.

Morton LM et al. Rationale and design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr. 2014;2014:1–14. doi:10.1093/jncimonographs/lgu005.PubMedCentralCrossRefPubMed

39.

Morton LM et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014:130–44. doi:10.1093/jncimonographs/lgu013.PubMedCentralCrossRefPubMed

40.

Monnereau A et al. Medical history, lifestyle, and occupational risk factors for hairy cell leukemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014:115–24. doi:10.1093/jncimonographs/lgu004.PubMedCentralCrossRefPubMed

41.••

Bracci PM et al. Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014:52–65. doi:10.1093/jncimonographs/lgu011. The largest pooled analysis of epidemiological risk factors for patients with marginal zone lymphoma.

42.

Aschebrook-Kilfoy B et al. Medical history, lifestyle, family history, and occupational risk factors for mycosis fungoides and Sezary syndrome: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014:98–105. doi:10.1093/jncimonographs/lgu008.PubMedCentralCrossRefPubMed

43.

Flowers CR, Armitage JO. A decade of progress in lymphoma: advances and continuing challenges. Clin Lymphoma Myeloma Leuk. 2010;10:414–23. doi:10.3816/CLML.2010.n.086.CrossRefPubMed

44.

Sinha R, Nastoupil L, Flowers CR. Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future. Blood Lymphat Cancer Targets Ther. 2012;2012:87–98. doi:10.2147/blctt.s18701.

45.

Alizadeh AA et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–11. doi:10.1038/35000501.CrossRefPubMed

46.

Rosenwald A et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–47. doi:10.1056/NEJMoa012914.CrossRefPubMed

47.

Fu K et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:4587–94. doi:10.1200/jco.2007.15.9277.CrossRef

48.

Tan DE et al. Genome-wide association study of B cell non-Hodgkin lymphoma identifies 3q27 as a susceptibility locus in the Chinese population. Nat Genet. 2013;45:804–7. doi:10.1038/ng.2666.CrossRefPubMed

49.

Cao HY, Zou P, Zhou H. Genetic association of interleukin-10 promoter polymorphisms and susceptibility to diffuse large B-cell lymphoma: a meta-analysis. Gene. 2013;519:288–94. doi:10.1016/j.gene.2013.01.066.CrossRefPubMed

50.

Hu W et al. Polymorphisms in pattern-recognition genes in the innate immunity system and risk of non-Hodgkin lymphoma. Environ Mol Mutagen. 2013;54:72–7. doi:10.1002/em.21739.CrossRefPubMed

51.

Khorshied MM, Gouda HM, Khorshid OM. Association of cytotoxic T-lymphocyte antigen 4 genetic polymorphism, hepatitis C viral infection and B-cell non-Hodgkin lymphoma: an Egyptian study. Leuk Lymphoma. 2014;55:1061–6. doi:10.3109/10428194.2013.820294.CrossRefPubMed

52.

Hosgood 3rd HD et al. IL10 and TNF variants and risk of non-Hodgkin lymphoma among three Asian populations. Int J Hematol. 2013;97:793–9. doi:10.1007/s12185-013-1345-5.PubMedCentralCrossRefPubMed

53.•

Bassig BA et al. Genetic susceptibility to diffuse large B-cell lymphoma in a pooled study of three Eastern Asian populations. Eur J Haematol. 2015. doi:10.1111/ejh.12513. A useful pooled analysis of genetic risk factors for diffuse large B-cell lymphoma.

54.

Sun YY, An L, Xie YL, Xu JY, Wang J. Methylenetetrahydrofolate reductase gene polymorphisms association with the risk of diffuse large B cell lymphoma: a meta-analysis. Tumour Biol J Int Soc Oncodev Biol Med. 2013;34:3587–91. doi:10.1007/s13277-013-0938-1.CrossRef

55.

Blount BC et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci. 1997;94:3290–5.PubMedCentralCrossRefPubMed

56.•

Bulka C et al. Residence proximity to benzene release sites is associated with increased incidence of non-Hodgkin lymphoma. Cancer. 2013;119:3309–17. doi:10.1002/cncr.28083. A geospatial analysis of the relationships between passive residential environmental exposures and risk of non-Hodgkin lymphoma.

57.•

Wang SS et al. Associations of non-Hodgkin lymphoma (NHL) risk with autoimmune conditions according to putative NHL loci. Am J Epidemiol. 2015. doi:10.1093/aje/kwu290. An interesting exploration of the interactions between auto-immune diseases and genetic risk factors for non-Hodgkin lymphoma.

58.

Swerdlow SH, International Agency for Research on Cancer & World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edn, (International Agency for Research on Cancer) 2008.

59.

Ambinder AJ et al. Exploring risk factors for follicular lymphoma. Adv Hematol. 2012;13:2012. doi:10.1155/2012/626035.

60.

Friedberg JW et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:1202–8. doi:10.1200/jco.2008.18.1495.CrossRef

61.

Solal-Celigny P, Cahu X, Cartron G. Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? Int J Hematol. 2010;92:246–54. doi:10.1007/s12185-010-0674-x.CrossRefPubMed

62.

Roulland S et al. Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis. J Exp Med. 2006;203:2425–31. doi:10.1084/jem.20061292.PubMedCentralCrossRefPubMed

63.

Smedby KE et al. GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet. 2011;7:e1001378. doi:10.1371/journal.pgen.1001378.PubMedCentralCrossRefPubMed

64.

Conde L et al. Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet. 2010;42:661–4. doi:10.1038/ng.626.PubMedCentralCrossRefPubMed

65.

Skibola CF et al. Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. Nat Genet. 2009;41:873–5. doi:10.1038/ng.419.PubMedCentralCrossRefPubMed

66.

Vijai J et al. Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies. PLoS Genet. 2013;9:e1003220. doi:10.1371/journal.pgen.1003220.PubMedCentralCrossRefPubMed

67.

Skibola CF et al. A meta-analysis of genome-wide association studies of follicular lymphoma. BMC Genomics. 2012;13:516. doi:10.1186/1471-2164-13-516.PubMedCentralCrossRefPubMed

68.

Skibola CF et al. Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region. Am J Hum Genet. 2014;95:462–71. doi:10.1016/j.ajhg.2014.09.004.PubMedCentralCrossRefPubMed

69.

Charbonneau B et al. CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. Cancer Immunol Immunother CII. 2013;62:1475–84. doi:10.1007/s00262-013-1452-4.CrossRefPubMed

70.

Fu A et al. Targetome profiling and functional genetics implicate miR-618 in lymphomagenesis. Epigenetics Off J DNA Methylation Soc. 2014;9:730–7. doi:10.4161/epi.27996.CrossRef

71.

Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16:2780–95.

72.

Wu SJ et al. The incidence of chronic lymphocytic leukemia in Taiwan, 1986-2005: a distinct increasing trend with birth-cohort effect. Blood. 2010;116:4430–5. doi:10.1182/blood-2010-05-285221.CrossRefPubMed

73.

Clarke CA et al. Lymphoid malignancies in U.S. Asians: incidence rate differences by birthplace and acculturation. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2011;20:1064–77. doi:10.1158/1055-9965.epi-11-0038.CrossRef

74.

Berndt SI et al. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet. 2013;45:868–76. doi:10.1038/ng.2652.PubMedCentralCrossRefPubMed

75.

Slager SL et al. Mapping of the IRF8 gene identifies a 3’UTR variant associated with risk of chronic lymphocytic leukemia but not other common non-Hodgkin lymphoma subtypes. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2013;22:461–6. doi:10.1158/1055-9965.epi-12-1217.CrossRef

76.

Malfertheiner P et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report. Gut. 2007;56:772–81. doi:10.1136/gut.2006.101634.PubMedCentralCrossRefPubMed

77.

Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808–25. doi:10.1111/j.1572-0241.2007.01393.x.CrossRefPubMed

78.

Vijai J et al. A genome-wide association study of marginal zone lymphoma shows association to the HLA region. Nat Commun. 2015;6:5751. doi:10.1038/ncomms6751.PubMedCentralCrossRefPubMed

79.

Love C et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012;44:1321–5. doi:10.1038/ng.2468.PubMedCentralCrossRefPubMed

80.

Zhang J et al. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood. 2014;123:2988–96. doi:10.1182/blood-2013-07-517177.PubMedCentralCrossRefPubMed

81.

Miyazaki K et al. Gene expression profiling of peripheral T-cell lymphoma including gammadelta T-cell lymphoma. Blood. 2009;113:1071–4. doi:10.1182/blood-2008-07-166363.CrossRefPubMed

82.

Vasmatzis G et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood. 2012;120:2280–9. doi:10.1182/blood-2012-03-419937.CrossRefPubMed

83.

Sakata-Yanagimoto M et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46:171–5. doi:10.1038/ng.2872.CrossRefPubMed

84.

de Leval L et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109:4952–63. doi:10.1182/blood-2006-10-055145.CrossRefPubMed

85.

Martinez-Delgado B et al. Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10:4971–82. doi:10.1158/1078-0432.ccr-04-0269.CrossRef

86.

Piccaluga PP et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest. 2007;117:823–34. doi:10.1172/jci26833.PubMedCentralCrossRefPubMed

87.

Imam MH, Shenoy PJ, Flowers CR, Phillips A, Lechowicz MJ. Incidence and survival patterns of cutaneous T-cell lymphomas in the United States. Leuk Lymphoma. 2013;54:752–9. doi:10.3109/10428194.2012.729831.CrossRefPubMed

88.

Abouyabis AN, Shenoy PJ, Lechowicz MJ, Flowers CR. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk lymphoma. 2008;49:2099–107. doi:10.1080/10428190802455867.CrossRefPubMed

89.

Flowers CR, Glover R, Lonial S, Brawley OW. Racial differences in the incidence and outcomes for patients with hematological malignancies. Curr Probl Cancer. 2007;31:182–201. doi:10.1016/j.currproblcancer.2007.01.005.CrossRefPubMed

90.

Flowers CR, Nastoupil LJ. Socioeconomic disparities in lymphoma. Blood. 2014;123:3530–1. doi:10.1182/blood-2014-04-568766.PubMedCentralCrossRefPubMed

91.

Flowers CR, Pro B. Racial differences in chronic lymphocytic leukemia. Digging deeper. Cancer. 2013;119:3593–5.PubMedCentralPubMed

92.

Shenoy PJ et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer. 2011;117:2530–40. doi:10.1002/cncr.25765.CrossRefPubMed

93.

Shenoy PJ et al. Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States. Clin Lymphoma Myeloma Leuk. 2011;11:498–506. doi:10.1016/j.clml.2011.07.002.CrossRefPubMed

94.

Wang SS et al. Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Cancer Res. 2007;67:5042–54. doi:10.1158/0008-5472.can-06-4752.CrossRefPubMed

95.

Heesen M, Kunz D, Bachmann-Mennenga B, Merk HF, Bloemeke B. Linkage disequilibrium between tumor necrosis factor (TNF)-alpha-308 G/A promoter and TNF-beta NcoI polymorphisms: association with TNF-alpha response of granulocytes to endotoxin stimulation. Crit Care Med. 2003;31:211–4. doi:10.1097/01.ccm.0000037167.19790.52.CrossRefPubMed

96.

Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci. 1997;94:3195–9.PubMedCentralCrossRefPubMed

97.

Romagnani S. Human Th17 cells. Arthritis Res Ther. 2008;10:206. doi:10.1186/ar2392.PubMedCentralCrossRefPubMed

98.

Oukka M. Interplay between pathogenic Th17 and regulatory T cells. Ann Rheum Dis. 2007;66(3):87–90. doi:10.1136/ard.2007.078527.

99.

Korn T, Oukka M, Kuchroo V, Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin Immunol. 2007;19:362–71. doi:10.1016/j.smim.2007.10.007.PubMedCentralCrossRefPubMed

Titel: To Each Its Own: Linking the Biology and Epidemiology of NHL Subtypes
verfasst von: Jean L. Koff
Dai Chihara
Anh Phan
Loretta J. Nastoupil
Jessica N. Williams
Christopher R. Flowers
Publikationsdatum: 01.09.2015
Verlag: Springer US
Erschienen in: Current Hematologic Malignancy Reports / Ausgabe 3/2015
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-015-0267-0

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

To Each Its Own: Linking the Biology and Epidemiology of NHL Subtypes

Abstract

Neu im Fachgebiet Onkologie

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

Persistent Disparities in Adult Hematopoietic Cell Transplantation

Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?

Incidence and Burden of the Myelodysplastic Syndromes

Financial Hardship—an Unwanted Consequence of Cancer Treatment

Treating Burkitt Lymphoma in Adults

Where Does Lenalidomide Fit in Non-del(5q) MDS?

Neu im Fachgebiet Onkologie

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Update Onkologie